BOULDER — OnKure Inc., a Boulder-based developer of oncology treatments, has appointed Mark Boys as vice president of discovery chemistry.
The company noted Boys’ “more than 25 years of research and managerial expertise within large and small life science companies.”
Boys previously worked at Pfizer Inc. as a senior director of medicinal chemistry, and at Boulder-based Array BioPharma Inc., which Pfizer acquired in 2019.
“Mark is an accomplished scientific researcher and leader in the biopharmaceutical industry, with extensive experience working at the interface of medicinal and process chemistry,” Tony Piscopio, co-founder, president and CEO of OnKure, said in a prepared statement.. “Having successfully discovered multiple candidates for clinical development, including in the oncology setting, we are looking forward to leveraging Mark’s knowledge as we continue to advance and expand our discovery pipeline of preclinical oncology programs.”
Boys said that “With its team of proven drug discovery and development scientists, OnKure is uniquely positioned to create a robust portfolio of novel oncology candidates designed to achieve optimal tolerability and efficacy.”